Nasdaq-listed Silo Pharma, Inc. (SILO) has thrust itself into the vanguard of decentralized science, or DeSci, with its strategic acquisition of ResearchCoin (RSC) tokens from ResearchHub on October 6, 2025, followed by November updates signaling deeper integration. This move, part of Silo’s expanded digital assets treasury, positions the developmental-stage biopharma firm to tokenize the sprawling $1 trillion global research economy, enabling liquid grants, on-chain intellectual property, or IP, management, and crowdsourced funding. “By securing a position in RSC, we are participating in the growing decentralized science movement while pursuing asset diversification and potential appreciation for shareholders,” said Eric Weisblum, CEO of Silo Pharma, in the October GlobeNewswire release. As traditional biotech funding stagnates amid 4.2 percent inflation eroding grants, Silo’s bet underscores a seismic pivot: crypto treasuries as engines for innovation, where RSC facilitates tokenized peer reviews and liquid incentives to accelerate discoveries by up to 40 percent.
DeSci’s ascent in 2025 is nothing short of explosive. Global funding for DeSci projects has ballooned to $637 million by mid-year, a 260 percent surge from 2024, comprising 11 percent of blockchain venture capital, per TokenMinds analysis. The sector’s market capitalization now tops $911 million across 55 projects, with tokenized IP assets exceeding 1,500 and DAOs like VitaDAO deploying over $10 million to longevity research in the past three years. ResearchHub, co-founded in 2019 by Coinbase CEO Brian Armstrong, powers this ecosystem with RSC as its native token, rewarding contributions like data sharing and peer reviews on a blockchain platform that has indexed thousands of papers. Silo’s November follow-up—revealed in a community call on October 13—detailed plans to leverage RSC for on-chain grants, potentially unlocking $50 billion in tokenized RWAs for biotech by year-end, as forecasted by Ozean reports. This aligns with a broader trend: 27 percent of DeSci projects now generate revenue through tokens, outpacing government grants at 6 percent, according to a Frontiers in Blockchain study.
A vivid real-world parallel is Molecule’s IP-NFT model, which tokenized biotech patents in Q2 2025, raising $12 million via DAO governance and accelerating a cancer therapeutic from lab to phase 1 trials in nine months—40 percent faster than the 15-month industry average, per EY biopharma data. Silo’s RSC stake mirrors this, enabling biotech firms to issue liquid grants where researchers stake tokens for milestones, verified via smart contracts. In a November X post, DeSci News highlighted the acquisition as a “bridge between big pharma and on-chain science,” sparking 39 likes and discussions on how RSC’s prediction markets could forecast trial outcomes with 92 percent accuracy. For Silo, this isn’t mere speculation; it’s a treasury play amid biotech’s $546 billion investment boom, where AI-DeSci hybrids claim 28 percent of deals, slashing development costs by 70 percent.
Yet 2025’s DeSci fervor carries risks: exploits siphoned $1.8 billion from DeFi-adjacent protocols in Q1, with 22 percent tied to unpatched smart contract flaws, per Chainalysis. Biotech firms eyeing crypto treasuries must fortify defenses. Allocate no more than 10 percent of reserves to tokens like RSC, diversifying across chains—bridge 20 percent to Ethereum for liquidity while staking on Solana for yields. Audit IP-NFT contracts quarterly with tools like Slither to evade reentrancy vulnerabilities, and implement multi-signature wallets for grant disbursements, cutting breach odds by 75 percent. Monitor on-chain peer reviews via oracles like Chainlink to prevent sybil attacks, which plagued 12 percent of DAOs, and conduct phishing drills—82 percent of breaches start there. For RSC specifically, verify contributions with zero-knowledge proofs to ensure HIPAA-compliant data sharing in health research.
The takeaway rings clear: biotech firms can diversify via crypto treasuries like Silo’s, where RSC enables on-chain peer reviews and crowdsourced funding, potentially accelerating discoveries by 40 percent through equitable, borderless capital. As DeSci TVL eyes $2.6 billion by 2026 and tokenized research claims 10 percent of the $1 trillion economy, traditional models—plagued by 88 percent data silos—face obsolescence.
Biotech leaders, the tokenization tide surges. Acquire RSC for your treasury today, pilot on-chain grants tomorrow, and audit relentlessly now. In DeSci’s dawn, diversification isn’t optional—it’s the accelerator for breakthroughs that redefine medicine. Stake your claim. Fund the future. Innovate without borders.
